{"entity":{"id":"wd-940","kind":"drug","name":"WD-940","aka":[],"tldr":"WD-940 is an experimental small molecule from Zhejiang Wenda Pharma, in preclinical development for advanced cancer; its current status is not stated.","summary":"WD-940 is a small molecule from Zhejiang Wenda Pharma. Described only as a brain-penetrant inhibitor of a mutant protein; the company compares it with BI-1810631 and NVL-330 but does not name the target. Its furthest stage is preclinical development, for advanced cancer (unspecified). No clinical trial naming it is registered on ClinicalTrials.gov. The page said WD-940 was expected to enter the clinic in 2024; no registered trial was found on ClinicalTrials.gov. It has not been shown to work in people.","status":"preclinical","asOf":"2026-11-03","links":[{"label":"Zhejiang Wenda Pharma: wendapharma.com","url":"https://www.wendapharma.com/pipeline.php"},{"label":"Zhejiang Wenda Pharma: wendapharma.com","url":"https://www.wendapharma.com/pipeline.php"}],"tags":["pipeline"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["zhejiang-wenda-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"WD-940","modality":"Small molecule","mechanism":"Described only as a brain-penetrant inhibitor of a mutant protein; the company compares it with BI-1810631 and NVL-330 but does not name the target.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/wd-940/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"zhejiang-wenda-pharma","kind":"company","name":"Zhejiang Wenda Pharma","route":"/companies/zhejiang-wenda-pharma/"}]}}